Mme Docteur PAULINE BAUDART

Bibliographie

• New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case–control MISSIL study

  2022

  ArticleRheumatology

• Clinical phenotype and cytokine profile of adult IgA vasculitis with joint involvement

  2022

  ArticleClinical Rheumatology

• Lamin A/C gene (LMNA) mutation associated with laminopathy: A rare cause of idiopathic acro-osteolysis

  2019

  ArticleJoint Bone Spine

• Bone sarcoidosis

  2018

  ArticleJoint Bone Spine

• Atypical juxta-articular form of Dercum's disease in a patient treated with tocilizumab for rheumatoid arthritis

  2018

  ArticleJoint Bone Spine

• Hypercalcémie sous étanercept : à quoi faut-il penser ?

  2018

  ArticleAlternative and Complementary Therapies

• FDG PET-CT as a powerful tool for diagnosing and monitoring treatment outcomes of relapsing polychondritis

  2018

  ArticleEuropean Journal of Nuclear Medicine and Molecular Imaging

• Association between osteoarthritis and dyslipidaemia: a systematic literature review and meta-analysis

  2017

  ArticleRMD Open

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieux de consultation

• CHU CAEN

  Avenue COTE DE NACRE, 14033 Caen

  ☎ 0231063106Hospitalier🏥 Centre CHU ↗🏥 Voir cet établissement

• PAULINE BAUDART

  18 RUE DES ROQUEMONTS, 14000 Caen

  Libéral
  67 m132 m133 m146 m

  © OpenStreetMap · Photos Wikimedia Commons (CC)

  📷 Street View ↗🗺️ Maps ↗OSM ↗

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Association between osteoarthritis and dyslipidaemia: a systematic literature review and meta-analysis

  RMD open · 2017

  📚 61 citations🎯 RCR 2.82Top 17% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Objectives We aimed to investigate the prevalence of dyslipidemia in patients with osteoarthritis (OA) and whether OA and dyslipidemia are associated. Methods We performed a systematic literature review and a meta-analysis, including cross-sectional, cohort and case–control studies, to assess the number of patients with OA and/or dyslipidemia. We calculated the mean (±SD) prevalence of dyslipidemia in patients with and without OA and the risk of dyslipidemia (OR, 95% CI) among patients with OA. Results From 605 articles screened, 48 were included in the analysis (describing 29 cross-sectional, 10 cohort and 9 case–control studies). The mean prevalence of dyslipidemia was 30.2%±0.6% among 14 843 patients with OA and 8.0%±0.1% among 196 168 without OA. The risk of dyslipidemia was greater with than without OA overall (OR 1.98,95% CI 1.43 to 2.75, p<0.0001) and with knee OA (OR 2.27, 1.33 to 3.89, p=0.003) and hand OA (OR 2.12, 1.46 to 3.07), p<0.0001). Conclusion The risk of dyslipidemia was twofold greater with than without OA, so lipid disturbances could be a risk factor for OA. Such a result supports the individualisation of the metabolic syndrome-associated OA phenotype.

• 2

  Clinical phenotype and cytokine profile of adult IgA vasculitis with joint involvement

  Clinical rheumatology · 2022

  📚 12 citations🎯 RCR 1.64
• 3

  New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study

  Rheumatology (Oxford, England) · 2022

  📚 8 citations

  Lire l'abstract Crossref ↓

  Abstract Objectives To describe new-onset IBD (new IBD) in patients treated with IL-17 inhibitors (IL-17i), to assess their incidence and to identify their risk factors in real life. Methods A French national registry (MISSIL) aimed to report all cases of new IBD in patients treated with IL-17i from January 2016 to December 2019. Using the estimated number of patients treated by IL-17 in France during the study period, the annual incidence rates of new IBD was reported in IL-17i-treated patients. A case–control study was performed with two controls per new IBD case matched by gender, age and underlying inflammatory disease. Results Thirty-one cases of new IBD under IL-17i were collected: 27 patients treated for spondyloarthritis and four patients for psoriasis. All were observed with secukinumab (SEK). The median time to onset of new IBD symptoms was 4.0 (1.5–7.5) months. SEK was discontinued in all patients. The evolution was favourable with complete resolution (17/31), improvement (7/31) or stabilization (5/31). Two patients died: one due to a massive myocardial infarction and one due to post-colectomy complications. The incidence of new IBD decreased from 0.69/100 patient-years [PY] (7/1010) in 2016 to 0.08/100 PY (6/7951) in 2019. No previous treatment with etanercept (odds ratio [OR] = 0.33, 95% CI: 0.14–0.80, P = 0.014) and low number of previous biologic therapies (OR = 0.67, 95% CI: 0.47, 0.94, P = 0.021) were significantly associated with new IBD. Conclusion The incidence of new IBD was low and decreased from 2016 to 2019. The outcome was favourable in 24 out of 31 patients, but two patients died.

Publications scientifiques (10) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche